Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Genticel S.A.. (9/1/15). "Press Release: Genticel to Meet Investors". Paris & Toulouse.

Organisations Organisation Genticel S.A. (Euronext Paris + Brussels: GTCL)
  Today Genkyotex S.A. (Euronext Paris + Brussels: GKTX)
  Group Genkyotex (Group)
  Organisation 2 KBC Group (Group) [since 3/05]
Products Product KBC Securities Benelux Biotech & Healthcare Conference 2015 New York
  Product 2 J.P. Morgan 34th Annual Healthcare Conference 2016 San Francisco
Index terms Index term Genticel–KBC: investor conference, 201511 supply service Genticel participates in KBC Biotech & Healthcare Seminar in New York
  Index term 2 Genticel–JPMorgan Chase: investor conference, 201601 supply service Genticel presents at JP Morgan Healthcare Conference 2016
Persons Person Leroy, Valerie (Onxeo 201612– Director IR + Corp Communications before Genticel + Carmat + Edwards Lifesciences)
  Person 2 Puissant, Corinne (Actus Finance et Communication 201404)

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announced its investor meeting programs for the coming months.

These events will be an opportunity for Genticel management to discuss recent company news, strategy and the latest developments of Genticel’s pipeline.

> Large & Midcap Event, taking place in Paris – Palais Brogniart, on October 7 & 8, 2015

> KBC Biotech & Healthcare Seminar taking place in New York on November 10, 2015

> Salon Actionaria, taking place in Paris – Palais des congrès on November 20 & 21, 2015

> JP Morgan Healthcare Conference taking place in San Francisco, from January 11 to 15, 2016

Results for the first half of 2015 will be published on September 21, 2015 (after markets close).

About Genticel

Aiming to solve a public health issue.

Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001 (known in Europe as ProCervix), its first-in-class immunotherapeutic vaccine candidate. The company has already completed patient recruitment for the phase 2 clinical trial of GTL001 in Europe. Offering a promising technological platform. Genticel’s versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel’s second candidate, GTL002, is a multivalent HPV therapeutic vaccine designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.

Focusing on value creation.

Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addtion to this attractive HPV product pipeline, Genticel’s versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIL), the world’s largest producer of vaccine doses. This partnership could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable SIIL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.

For more information, visit us at


This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genticel shares in any country. This press release may contain forwardlooking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company’s management and are subject to risks and uncertainties such as the company’s ability to implement its chosen strategy, customer market trends, changes in technologies and in the company’s competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company’s growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015 and those linked to changes in economic conditions, the financial markets, or the markets on which Genticel is present. Genticel products are currently used for clinical trials only and are not otherwise available for distribution or sale.

Valerie Leroy
Investor Relations & Corporate
+33 6 33 34 37 30


Brian Stollar – Life Sci Advisors
+1 212 915 2577

Corinne Puissant - ACTUS
+33 1 53 67 36 77

Caroline Carmagnol et
Florence Portejoie - ALIZE RP
+33 6 64 18 99 59 / +33 6 47 38 90

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Genkyotex (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top